Sign in or create an account to add this stock to your watchlist.
About PTC Therapeutics (NASDAQ:PTCT)
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy. It is developing Translarna, which is in Phase II clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 for the treatment of patients with spinal muscular atrophy, as well as PTC596, an orally bioavailable and potent small molecule that has completed Phase I study, which targets solid tumor cell populations by reducing the activity and amount of BMI1. The company has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and research collaboration with CHDI Foundation, Inc. to discover and develop small-molecule therapeutics for Huntington's disease. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PTCT
CUSIPN/A
Phone908-222-7000
Debt
Debt-to-Equity Ratio0.98
Current Ratio3.33
Quick Ratio3.16
Price-To-Earnings
Trailing P/E Ratio-15.11
Forward P/E Ratio-19.69
P/E GrowthN/A
Sales & Book Value
Annual Sales$194.39 million
Price / Sales7.29
Cash FlowN/A
Price / CashN/A
Book Value$3.77 per share
Price / Book8.10
Profitability
EPS (Most Recent Fiscal Year)($2.02)
Net Income$-79,000,000.00
Net Margins-30.91%
Return on Equity-40.42%
Return on Assets-16.53%
Miscellaneous
Employees373
Outstanding Shares46,450,000
PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions
What is PTC Therapeutics' stock symbol?
PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."
How were PTC Therapeutics' earnings last quarter?
PTC Therapeutics (NASDAQ:PTCT) announced its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.03. The biopharmaceutical company had revenue of $56.10 million for the quarter, compared to analyst estimates of $63.46 million. PTC Therapeutics had a negative return on equity of 40.42% and a negative net margin of 30.91%. The firm's quarterly revenue was up 111.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.85) earnings per share. View PTC Therapeutics' Earnings History.
When is PTC Therapeutics' next earnings date?
What price target have analysts set for PTCT?
8 equities research analysts have issued 12-month target prices for PTC Therapeutics' shares. Their forecasts range from $15.00 to $35.00. On average, they anticipate PTC Therapeutics' share price to reach $22.6667 in the next year. View Analyst Ratings for PTC Therapeutics.
What are Wall Street analysts saying about PTC Therapeutics stock?
Here are some recent quotes from research analysts about PTC Therapeutics stock:
- 1. William Blair analysts commented, "CX-072 Data at ASCO. CTMX’s lead proprietary program, CX-072, will have first in human data at ASCO, both monotherapy (A") arm and combination with ipilimumab (B") arm. Since these data are early and not complete data sets, high levels of response rates may not be likely, but we think activity, even a modest level, could represent upside for the shares given that this is first in human data. We think a key proof of the technology will be measurement of systemically active versus intact" Probody CX-072." (5/10/2018)
- 2. According to Zacks Investment Research, "PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. " (5/9/2018)
- 3. Cowen Inc analysts commented, "Yesterday Clearside announced the completion of enrollment in the TYBEE study in." (10/25/2017)
Are investors shorting PTC Therapeutics?
PTC Therapeutics saw a decrease in short interest in the month of April. As of April 13th, there was short interest totalling 4,260,918 shares, a decrease of 22.8% from the March 30th total of 5,521,035 shares. Based on an average trading volume of 873,026 shares, the days-to-cover ratio is presently 4.9 days. Currently, 10.8% of the company's shares are sold short.
Who are some of PTC Therapeutics' key competitors?
Some companies that are related to PTC Therapeutics include Ionis Pharmaceuticals (IONS), Catalent (CTLT), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), GW Pharmaceuticals (GWPH), FibroGen (FGEN), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY) and Ultragenyx Pharmaceutical (RARE).
Who are PTC Therapeutics' key executives?
PTC Therapeutics' management team includes the folowing people:
- Dr. Stuart W Peltz, Co-Founder, CEO & Exec. Director (Age 58)
- Dr. Allan Steven Jacobson, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 72)
- Dr. Neil Almstead Ph.D., Exec. VP of Research, Pharmaceutical Operations & Technology (Age 51)
- Mr. Mark Elliott Boulding, Chief Legal Officer, EVP & Sec. (Age 57)
- Ms. Christine Utter, Principal Financial & Accounting Officer and Treasurer
Has PTC Therapeutics been receiving favorable news coverage?
News headlines about PTCT stock have trended somewhat positive on Tuesday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. PTC Therapeutics earned a media sentiment score of 0.17 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 47.37 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are PTC Therapeutics' major shareholders?
PTC Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Scopia Capital Management LP (12.73%), BlackRock Inc. (7.07%), Millennium Management LLC (1.46%), Northern Trust Corp (1.43%), Spark Investment Management LLC (1.41%) and Frontier Capital Management Co. LLC (1.40%). Company insiders that own PTC Therapeutics stock include Christine Marie Utter, Dawn Svoronos, Neil Gregory Almstead and Stuart Walter Peltz. View Institutional Ownership Trends for PTC Therapeutics.
Which institutional investors are selling PTC Therapeutics stock?
PTCT stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, Dimensional Fund Advisors LP, Asymmetry Capital Management L.P., American Century Companies Inc., UBS Group AG, South Dakota Investment Council, Guggenheim Capital LLC and Pinnacle Associates Ltd.. Company insiders that have sold PTC Therapeutics company stock in the last year include Christine Marie Utter, Neil Gregory Almstead and Stuart Walter Peltz. View Insider Buying and Selling for PTC Therapeutics.
Which institutional investors are buying PTC Therapeutics stock?
PTCT stock was acquired by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Frontier Capital Management Co. LLC, BlackRock Inc., Opaleye Management Inc., Millennium Management LLC, Candriam Luxembourg S.C.A., Schwab Charles Investment Management Inc. and Federated Investors Inc. PA. View Insider Buying and Selling for PTC Therapeutics.
How do I buy shares of PTC Therapeutics?
Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PTC Therapeutics' stock price today?
One share of PTCT stock can currently be purchased for approximately $30.52.
How big of a company is PTC Therapeutics?
PTC Therapeutics has a market capitalization of $1.49 billion and generates $194.39 million in revenue each year. The biopharmaceutical company earns $-79,000,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. PTC Therapeutics employs 373 workers across the globe.
How can I contact PTC Therapeutics?
PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected]
MarketBeat Community Rating for PTC Therapeutics (PTCT)
MarketBeat's community ratings are surveys of what our community members think about PTC Therapeutics and other stocks. Vote "Outperform" if you believe PTCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
PTC Therapeutics (NASDAQ:PTCT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for PTC Therapeutics in the last 12 months. Their average twelve-month price target is $22.6667, suggesting that the stock has a possible downside of 25.73%. The high price target for PTCT is $35.00 and the low price target for PTCT is $15.00. There are currently 2 sell ratings, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.00 | 2.13 | 2.11 |
| Ratings Breakdown: | 2 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $22.6667 | $22.6667 | $20.8333 | $18.1429 |
| Price Target Upside: | 25.73% downside | 13.22% downside | 13.70% downside | 19.83% upside |
PTC Therapeutics (NASDAQ:PTCT) Consensus Price Target History
PTC Therapeutics (NASDAQ:PTCT) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
PTC Therapeutics (NASDAQ:PTCT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
PTC Therapeutics (NASDAQ PTCT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.10%
Institutional Ownership Percentage: 91.70%
PTC Therapeutics (NASDAQ PTCT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/5/2018 | Stuart Walter Peltz | CEO | Sell | 2,230 | $18.03 | $40,206.90 | 26,646 |  |
| 1/4/2018 | Christine Marie Utter | Insider | Sell | 412 | $17.67 | $7,280.04 | | |
| 1/4/2018 | Neil Gregory Almstead | EVP | Sell | 77 | $17.67 | $1,360.59 | | |
| 5/23/2017 | Dawn Svoronos | Director | Buy | 25,000 | $13.49 | $337,250.00 | 25,000 | |
| 1/5/2017 | Neil Gregory Almstead | EVP | Sell | 78 | $11.82 | $921.96 | | |
| 3/3/2016 | Mark Rothera | Insider | Buy | 2,000 | $6.23 | $12,460.00 | 5,125 | |
| 7/6/2015 | David P Southwell | Director | Sell | 23,604 | $47.52 | $1,121,662.08 | | |
| 6/18/2015 | Allan Steven Jacobson | Director | Sell | 5,000 | $50.13 | $250,650.00 | | |
| 6/9/2015 | Stuart Walter Peltz | CEO | Sell | 100,000 | $54.49 | $5,449,000.00 | | |
| 6/8/2015 | Mark Elliott Boulding | VP | Sell | 56,849 | $55.04 | $3,128,968.96 | | |
| 6/8/2015 | Richard Aldrich | Director | Sell | 7,000 | $55.66 | $389,620.00 | | |
| 6/8/2015 | Stuart Walter Peltz | CEO | Sell | 73,700 | $54.91 | $4,046,867.00 | | |
| 5/22/2015 | Shane William Charles Kovacs | CFO | Sell | 82,491 | $55.41 | $4,570,826.31 | | |
| 4/15/2015 | Neil Gregory Almstead | EVP | Sell | 9,511 | $68.65 | $652,930.15 | | |
| 3/23/2015 | David P Southwell | Director | Sell | 2,317 | $69.04 | $159,965.68 | | |
| 3/23/2015 | Stuart Walter Peltz | CEO | Sell | 47,200 | $69.14 | $3,263,408.00 | | |
| 3/20/2015 | Mark Elliott Boulding | VP | Sell | 21,142 | $68.12 | $1,440,193.04 | | |
| 3/18/2015 | Allan Steven Jacobson | Director | Sell | 16,616 | $76.00 | $1,262,816.00 | | |
| 3/17/2015 | Mark Rothera | Insider | Sell | 10,700 | $76.64 | $820,048.00 | | |
| 3/16/2015 | Michael L Kranda | Director | Sell | 2,500 | $72.81 | $182,025.00 | | |
| 3/13/2015 | Robert J Spiegel | Insider | Sell | 1,030 | $75.10 | $77,353.00 | | |
| 3/10/2015 | Neil Gregory Almstead | EVP | Sell | 79 | $70.71 | $5,586.09 | | |
| 3/9/2015 | Stuart Walter Peltz | CEO | Sell | 47,201 | $70.74 | $3,338,998.74 | | |
| 2/25/2015 | Mark Rothera | Insider | Sell | 35,000 | $68.01 | $2,380,350.00 | | |
| 2/24/2015 | Mark Rothera | Insider | Sell | 1,000 | $67.70 | $67,700.00 | | |
| 2/23/2015 | Mark Rothera | Insider | Sell | 23,000 | $65.40 | $1,504,200.00 | | |
| 1/21/2015 | Neil Gregory Almstead | EVP | Sell | 26,096 | $60.26 | $1,572,544.96 | | |
| 1/20/2015 | Mark Rothera | Insider | Sell | 3,000 | $60.02 | $180,060.00 | | |
| 1/16/2015 | Mark Rothera | Insider | Sell | 2,300 | $58.67 | $134,941.00 | | |
| 1/15/2015 | Claudia De Oliveira Ri Hirawat | President | Sell | 2,149 | $57.19 | $122,901.31 | | |
| 1/14/2015 | Mark Rothera | Insider | Sell | 9,700 | $58.04 | $562,988.00 | | |
| 12/15/2014 | Claudia De Oliveira Ri Hirawat | President | Sell | 2,173 | $55.24 | $120,036.52 | | |
| 11/17/2014 | Claudia De Oliveira Ri Hirawat | President | Sell | 2,173 | $39.78 | $86,441.94 | | |
| 10/15/2014 | Claudia De Oliveira Ri Hirawat | President | Sell | 45,661 | $36.15 | $1,650,645.15 | | |
| 10/10/2014 | Claudia De Oliveira Ri Hirawat | President | Sell | 43,489 | $36.18 | $1,573,432.02 | | |
| 10/1/2014 | Stuart Walter Peltz | CEO | Sell | 41,501 | $42.65 | $1,770,017.65 | | |
| 9/26/2014 | Mark Rothera | Insider | Sell | 16,000 | $44.63 | $714,080.00 | | |
| 9/18/2014 | Allan Steven Jacobson | Director | Sell | 2,000 | $40.16 | $80,320.00 | | |
| 9/15/2014 | Mark Rothera | Insider | Sell | 8,000 | $36.24 | $289,920.00 | | |
| 5/22/2014 | Shane William Charles Kovacs | CFO | Sell | 1,650 | $14.74 | $24,321.00 | 12,350 | |
| 3/24/2014 | Stuart Walter Peltz | CEO | Sell | 25,487 | $29.86 | $761,041.82 | 135,902 | |
| 3/21/2014 | Claudia De Oliveira Ri Hirawat | President | Sell | 15,320 | $29.61 | $453,625.20 | 34,737 | |
| 3/21/2014 | David Southwell | Director | Sell | 2,317 | $30.93 | $71,664.81 | 10,921 | |
| 3/20/2014 | Mark Elliott Boulding | VP | Sell | 10,049 | $30.96 | $311,117.04 | 32,235 | |
| 3/19/2014 | Neil Gregory Almstead | VP | Sell | 10,859 | $31.91 | $346,510.69 | 29,881 | |
| 3/18/2014 | Allan Steven Jacobson | Director | Sell | 7,616 | $31.18 | $237,466.88 | 30,464 | |
| 3/14/2014 | Michael Kranda | Director | Sell | 1,186 | $31.02 | $36,789.72 | 4,742 | |
| 3/13/2014 | Robert Spiegel | Insider | Sell | 1,186 | $31.75 | $37,655.50 | 4,269 | |
| 3/7/2014 | Stuart Walter Peltz | CEO | Sell | 27,414 | $29.91 | $819,952.74 | 161,389 | |
| 12/17/2013 | Hbm Healthcare Investments (Ca | major shareholder | Sell | 66,667 | $19.08 | $1,272,006.36 | 2,441,504 | |
| 6/25/2013 | Adam Koppel | Director | Buy | 1,250,000 | $15.00 | $18,750,000.00 | | |
| 6/25/2013 | Hbm Healthcare Investments (Ca | Major Shareholder | Buy | 666,676 | $15.00 | $10,000,140.00 | | |
| 6/25/2013 | Mark Rothera | Insider | Buy | 25,000 | $15.00 | $375,000.00 | | |
(Data available from 1/1/2013 forward)
PTC Therapeutics (NASDAQ PTCT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Notice to Current PTC Stockholders: Rosen Law Firm Announces Preliminary Approval of Derivative Settlement on Behalf of PTC Therapeutics, Inc.
finance.yahoo.com - May 18 at 5:36 PM |
 | PTC Therapeutics (PTCT) Upgraded to Buy by ValuEngine
www.americanbankingnews.com - May 17 at 10:23 PM |
| Q2 2018 EPS Estimates for PTC Therapeutics Increased by Analyst (PTCT)
www.americanbankingnews.com - May 14 at 1:56 AM |
| PTC Therapeutics (PTCT) Downgraded to Hold at ValuEngine
www.americanbankingnews.com - May 11 at 9:23 PM |
| PTC Therapeutics (PTCT) Posts Earnings Results, Misses Estimates By $0.03 EPS
www.americanbankingnews.com - May 10 at 8:29 PM |
| PTC Therapeutics (PTCT) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 10 at 7:45 PM |
| William Blair Reiterates "Hold" Rating for PTC Therapeutics (PTCT)
www.americanbankingnews.com - May 10 at 1:02 PM |
 | PTC Therapeutics' (PTCT) CEO Stuart Peltz on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 8:42 AM |
| Edited Transcript of PTCT earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 8:42 AM |
| PTC Therapeutics Q1 revenues up 112%
seekingalpha.com - May 9 at 5:17 PM |
| PTC Therapeutics misses by $0.03, misses on revenue
seekingalpha.com - May 9 at 5:17 PM |
| PTC Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 5:17 PM |
| PTC Therapeutics Reports First Quarter 2018 Financial Results and Provides a Corporate Update
finance.yahoo.com - May 9 at 5:17 PM |
| PTC Therapeutics (PTCT) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 9 at 5:12 PM |
| Analysis: Positioning to Benefit within Entergy, Schneider National, C.H. Robinson Worldwide, PTC Therapeutics, Guess?, and Immunomedics — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - May 9 at 8:38 AM |
| PTC Therapeutics (PTCT) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - May 2 at 7:06 PM |
| PTC Therapeutics Target of Unusually Large Options Trading (PTCT)
www.americanbankingnews.com - May 2 at 6:58 AM |
 | Atara Biotherapeutics Expands Commercial Leadership Team with the Appointment of Manuela Maronati as General ...
globenewswire.com - May 1 at 8:41 AM |
| PTC Therapeutics to Participate at Upcoming Investor Conference
finance.yahoo.com - April 30 at 8:40 AM |
| PTC Therapeutics (PTCT) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 8:34 AM |
| PTC Therapeutics (PTCT) Short Interest Update
www.americanbankingnews.com - April 28 at 2:54 AM |
 | June 8th Options Now Available For PTC Therapeutics (PTCT)
www.nasdaq.com - April 26 at 5:05 PM |
| PTC Therapeutics (PTCT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 19 at 3:34 PM |
| PTC Therapeutics (PTCT) Forecasted to Post Q1 2018 Earnings of ($0.61) Per Share
www.americanbankingnews.com - April 18 at 7:42 AM |
| PTC Therapeutics (PTCT) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 15 at 7:31 PM |
 | Free Research Reports on These Biotech Stocks -- Prothena, PTC Therapeutics, Pulmatrix, and Puma Biotech
www.prnewswire.com - April 13 at 7:22 AM |
| PTC Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - April 12 at 5:19 PM |
| PTC Therapeutics (PTCT) Downgraded by JPMorgan Chase
www.americanbankingnews.com - April 7 at 8:50 PM |
| PTC Therapeutics (PTCT) Downgraded by Bank of America
www.americanbankingnews.com - April 4 at 8:34 PM |
| PTC Therapeutics and CHDI Foundation Announce a Collaboration on a Small-Molecule Therapeutic for Huntington's Disease
finance.yahoo.com - April 4 at 8:39 AM |
| PTC Therapeutics (PTCT) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 3 at 9:18 PM |
| Barclays Lowers PTC Therapeutics (PTCT) to Underweight
www.americanbankingnews.com - April 3 at 5:16 PM |
| PTC Therapeutics (PTCT) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - March 30 at 1:18 PM |
| PTC Therapeutics Sees Unusually High Options Volume (PTCT)
www.americanbankingnews.com - March 30 at 7:06 AM |
| PTC Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 27 at 5:01 PM |
| Credit Suisse Group Reiterates Buy Rating for PTC Therapeutics (PTCT)
www.americanbankingnews.com - March 26 at 4:18 PM |
| PTC Therapeutics, Inc. (PTCT) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 21 at 7:36 PM |
| FIREFISH Transitions into Pivotal Phase - PR Newswire - PR Newswire (press release)
www.prnewswire.com - March 16 at 8:40 AM |
| FIREFISH Transitions into Pivotal Phase
finance.yahoo.com - March 15 at 8:34 AM |
| PTC Therapeutics (PTCT) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 10 at 6:06 AM |
| Q1 2018 EPS Estimates for PTC Therapeutics, Inc. (PTCT) Lowered by William Blair
www.americanbankingnews.com - March 9 at 7:26 AM |
| PTC Therapeutics, Inc. Forecasted to Earn Q1 2019 Earnings of ($0.38) Per Share (PTCT)
www.americanbankingnews.com - March 8 at 11:50 AM |
| PTC Therapeutics (PTCT) Price Target Raised to $24.00
www.americanbankingnews.com - March 7 at 4:15 PM |
| PTC Therapeutics (PTCT) Receives Hold Rating from William Blair
www.americanbankingnews.com - March 7 at 12:45 PM |
 | PTC Therapeutics Q4 Earnings Preview - Benzinga
www.benzinga.com - March 7 at 8:41 AM |
| Investor Expectations to Drive Momentum within AVEO Pharmaceuticals, PTC Therapeutics, NGL Energy Partners LP, Bemis, CorMedix, and Patterson Companies — Discovering Underlying Factors of Influence
finance.yahoo.com - March 7 at 8:41 AM |
| PTC Therapeutics (PTCT) Issues Quarterly Earnings Results, Beats Expectations By $0.25 EPS
www.americanbankingnews.com - March 6 at 9:12 PM |
| PTC Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 6 at 5:27 PM |
| PTC Therapeutics Q4 Earnings Preview
finance.yahoo.com - March 6 at 5:27 PM |
| PTC Therapeutics posts 4Q profit
finance.yahoo.com - March 6 at 5:27 PM |
PTC Therapeutics (NASDAQ:PTCT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
PTC Therapeutics (NASDAQ:PTCT) Income Statement, Balance Sheet and Cash Flow Statement
PTC Therapeutics (NASDAQ PTCT) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
